+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Sorafenib Market Size by Product, by Application, by Geographic Scope And Forecast

  • ID: 5301574
  • Report
  • March 2020
  • Region: Global
  • 90 Pages
  • Verified Market Research


  • Bayer AG
  • Cipla
  • Hetero Healthcare Ltd
  • Natco Pharma
Sorafenib Market Size And Forecast

According to the publisher, the Global Sorafenib Market was valued at USD 1.08 Billion in 2020 and is projected to reach USD 1.18 Billion by 2027, growing at a CAGR of 1.21% from 2020 to 2027.

Global Sorafenib Market Overview

Cancer remains among the leading causes of death worldwide. The rate of new cancer patients is on a constant rise. Cancer is a significant public health issue and is now considered as a potentially chronic disease. Advancements in the early diagnosis and treatments have significantly improved the cancer survival rate.

Sorafenib is primarily used in the treatment of renal cancer (kidney cancer), thyroid cancer, and liver cancer. The incidence of thyroid cancer has been increasing over the last few decades according to epidemiological research findings. The incidence of thyroid cancer in higher-income countries has been considerably rising and the global age-standardized incidence rate of thyroid cancer increased by approximately 20%. Similarly, with the surge in the liver and kidney cancer cases, the demand for anti-cancer drugs such as sorafenib is expected to rise.

Global Sorafenib Market: Segmentation Analysis

The Global Sorafenib Market is segmented on the basis of Product, Application, and Geography.

Global Sorafenib Market Competitive Landscape

The “Global Sorafenib Market” study report will provide a valuable insight with an emphasis on the global market including some of the major players such as Bayer AG, Cipla, Natco Pharma, and Hetero Healthcare Ltd.
Note: Product cover images may vary from those shown


  • Bayer AG
  • Cipla
  • Hetero Healthcare Ltd
  • Natco Pharma
1 Introduction
1.1 Market Definition
1.2 Market Segmentation
1.3 Research Timelines
1.4 Assumptions
1.5 Limitations

2 Research Methodology
2.1 Data Mining
2.2 Secondary Research
2.3 Primary Research
2.4 Subject Matter Expert Advice
2.5 Quality Check
2.6 Final Review
2.7 Data Triangulation
2.8 Bottom-Up Approach
2.9 Top Down Approach
2.1 Research Flow

3 Executive Summary
3.1 Market Overview
3.2 Global Sorafenib Market Geographical Analysis (Cagr %)
3.3 Global Sorafenib Market, by Product (Usd Million)
3.4 Global Sorafenib Market, by Application (Usd Million)
3.5 Future Market Opportunities
3.6 Global Market Split

4 Market Outlook
4.1 Global Sorafenib Market Outlook
4.2 Market Drivers
4.2.1 Rising Prevalence of Patients Suffering With Cancer
4.3 Market Restraints
4.3.1 Factors Preventing More Patients Benefitting from Sorafenib
4.3.2 Health Risks Associated With Sorafenib
4.4 Market Opportunity
4.4.1 Ongoing Research Studies for the Development of Effective Sorafenib Formulations
4.5 Market Challenges
4.5.1 Decreasing Sales of Sorafenib
4.5.2 Emergence of New Substitute Drugs
4.6 Impact of Covid-19 on Sorafenib Market

5 Market, by Product
5.1 Overview
5.2 Patented Drugs
5.3 Generic Drugs

6 Market, by Application
6.1 Overview
6.2 Kidney Cancer
6.3 Liver Cancer
6.4 Thyroid Cancer
6.5 Others

7 Market, by Geography
7.1 Overview
7.2 North America
7.2.1 U.S.
7.2.2 Canada
7.2.3 Mexico
7.3 Europe
7.3.1 Germany
7.3.2 U.K.
7.3.3 France
7.3.4 Rest of Europe
7.4 Asia-Pacific
7.4.1 China
7.4.2 India
7.4.3 Japan
7.4.4 Rest of Asia-Pacific
7.5 Rest of World
7.5.1 Middle East and Africa
7.5.2 Latin America

8 Competitive Landscape
8.1 Overview
8.2 Company Market Ranking Analysis

9 Company Profiles
9.1 Bayer AG
9.1.1 Company Overview
9.1.2 Company Insights
9.1.3 Segment Breakdown
9.1.4 Product Benchmarking
9.1.5 SWOT Analysis
9.2 Cipla
9.2.1 Company Overview
9.2.2 Company Insights
9.2.3 Segment Breakdown
9.2.4 Product Benchmarking
9.2.5 SWOT Analysis
9.3 Natco Pharma
9.3.1 Company Overview
9.3.2 Company Insights
9.3.3 Segment Breakdown
9.3.4 Product Benchmarking
9.3.5 SWOT Analysis
9.4 Hetero Healthcare
9.4.1 Company Overview
9.4.2 Company Insights
9.4.3 Product Benchmarking
9.4.4 SWOT Analysis
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Bayer AG
  • Cipla
  • Natco Pharma
  • Hetero Healthcare Ltd
Note: Product cover images may vary from those shown